



## **Oncimmune Signs Agreement with America's Choice Provider Network to Expand Access to its Blood Tests for the Early Detection of Lung and Liver Cancers**

De Soto, Kansas, December 20, 2018 – Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer, today announced that it has entered into an agreement with America's Choice Provider Network (ACPN) to expand access to Oncimmune's simple and affordable blood tests, **EarlyCDT®—Lung** and **EarlyCDT®—Liver**. ACPN is an independent, multi-specialty provider network accessed by over 1,700 payers. More than 28 million Americans and 750,000 international lives have access to ACPN's network.

**EarlyCDT—Lung** is used by clinicians to assess lung cancer risk in high-risk patients who have an indeterminate pulmonary nodule (IPN), and is highly specific in detecting all types of lung cancer at all stages of disease. These attributes make the test complementary to the high sensitivity but poor specificity of CT scanning. **EarlyCDT—Liver** aids in the detection and confirmation of hepatocellular carcinoma (HCC, liver cancer), in association with imaging, in high-risk patients with liver lesions of all sizes.

"Our collaboration with America's Choice Provider Network is one of several payor and provider agreements we have recently finalized to ensure as many people as possible in the U.S. are able to use our **EarlyCDT®** tests to facilitate earlier diagnoses," said Marco Casarin, General Manager, Oncimmune (USA) LLC. "Especially in lung cancer—with nearly 1.6 million Americans having an incidentally detected nodule on the lung—a positive **EarlyCDT—Lung** outcome enables quicker clinician intervention and better patient outcomes."

### **About Oncimmune®**

Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.

Oncimmune launched its platform technology in 2009, followed by its first commercial tests, **EarlyCDT®—Lung** and **EarlyCDT®—Liver**. To date, over 155,000 tests have been performed for patients worldwide. **EarlyCDT—Lung** is being used in the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland, which is the largest-ever randomized trial for the early detection of lung cancer using biomarkers.

Oncimmune is headquartered in Nottingham, UK, with a CLIA lab in Kansas, U.S. and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

For more information, visit <http://oncimmune.com/>. Follow us on [Twitter](#) and [LinkedIn](#).

---

Media Contact:

RAliance Communications  
Reba Auslander  
[reba@raliancecommunications.com](mailto:reba@raliancecommunications.com)  
917-836-9308

Consilium Strategic Communications  
Chris Gardner, Matthew Neal, Lindsey Neville  
[Oncimmune@consilium-comms.com](mailto:Oncimmune@consilium-comms.com)  
+44 (0)20 3709 5708